Pegenzileukin
As of the edition of 20 October 2026, Pegenzileukin is a protein: in active development; acts on IL2RB and IL2RG.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Protein
- Registered trials
- 8, 6 stopped early
- Disease areas
- Cancer; Blood and lymph; Digestive system; Ear, nose and throat; Immune system; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 8 | 1 | 1 | 6 |
| All trials | 8 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Sanofi | Lead sponsor of trials | 2019 to now |